ENLV, IL0011319527

Enlivex cuts workforce 60 percent as its Phase 2b trial advances Enlivex stock

Published on 10/20/2026 at 13:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Enlivex plans a 60 percent workforce cut for Allocetra. Enlivex stock costs EUR 0.19 on October 20, 2026 during trading.

Cost reduction and trial timeline

Enlivex announced its cost reduction plan on October 19, 2026.
The workforce reduction is 60 percent, while management pay will fall 20 percent.
Enlivex stock traded at EUR 0.19 at 1:10 p.m. CEST at Lang & Schwarz on October 20, 2026.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex Ltd. (ISIN IL0011319527) announced on October 19, 2026, that it will reduce its workforce by 60 percent and concentrate resources on the Phase 2b trial of Allocetra. The company expects topline six-month trial data by mid-2027, according to GlobeNewswire.

60 percent workforce reduction

The plan winds down research and development activities unrelated to the Phase 2b program and directs the remaining resources toward clinical execution. Management salaries will be reduced by 20 percent, while the chief executive officer's salary will be reduced by 40 percent, the October 19, 2026 release said.

The cost measures are designed to reduce cash burn, but the company also identified financing and trial execution as risks in its forward-looking statements. The Phase 2b study is global, multicenter, randomized, double-blind and placebo-controlled, evaluating Allocetra injections in patients aged 64 and older with moderate-to-severe age-related primary knee osteoarthritis.

What comes after the restructuring?

The next major company milestone is the expected mid-2027 release of six-month topline data from the Phase 2b trial. The program builds on a completed Phase 1/2a study in which Allocetra showed statistically significant improvements in knee pain and function compared with placebo at three and six months, according to the October 19, 2026 company release.

Three dated milestones

On July 30, 2026, Enlivex said Rain protocol trading volume reached USD 860 million in July, up 622 percent from June. On September 22, 2026, the company announced termination of a previously announced financing payable in RAIN tokens. On October 19, 2026, it announced the 60 percent workforce reduction and the Phase 2b focus.

Trial timing is the key date

Enlivex expects the Phase 2b six-month topline data by mid-2027. The timing is the clearest quantified milestone in the company's latest release and links the cost reduction plan to a defined clinical readout.

Enlivex stock remains a clinical-stage bet

Enlivex stock was trading at EUR 0.19 at Lang & Schwarz on October 20, 2026, at 1:10 p.m. CEST. The Nasdaq listing is ENLV, and the company is advancing Allocetra alongside a prediction markets treasury strategy, according to the October 19, 2026 company release. The further course of trading is shown by the continuously updated real-time quote of Enlv stock.